Teprotumumab - Horizon Therapeutics
Alternative Names: HZN 001; Insulin-like-growth-factor-1-receptor-antagonist-antibody-River-Vision-Development; R 1507; RG 1507; RO-4858696; RV 001-River-Vision; Tepezza; teprotumumab-trbwLatest Information Update: 29 Feb 2024
At a glance
- Originator Genmab; Roche
- Developer Halozyme Therapeutics; Horizon Therapeutics plc; Roche
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Apoptosis stimulants; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Graves ophthalmopathy
- No development reported Diabetic macular oedema; Diffuse scleroderma
- Discontinued Advanced breast cancer; Hodgkin's disease; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Sarcoma; Solid tumours
Most Recent Events
- 08 Feb 2024 Horizon Pharma plans a phase III trial for Graves ophthalmopathy (SC, Injection) in February 2024 (NCT06248619)
- 06 Feb 2024 Preregistration for Graves ophthalmopathy in Japan (IV) prior to February 2024
- 10 Jan 2024 Phase I development is ongoing for Graves ophthalmopathy in Ireland (SC) (Horizon Therapeutics pipeline, January 2024)